Last reviewed · How we verify
Duloxetine 60mg
At a glance
| Generic name | Duloxetine 60mg |
|---|---|
| Also known as | Cymbalta |
| Sponsor | Ain Shams University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) (PHASE1, PHASE2)
- Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough (PHASE2)
- Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough (PHASE2)
- Effect of peRiopErative duLoxetIne Administration on Opioid Consumption Following Total kneE Arthroplasty (RELIFE) (PHASE4)
- SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy. (PHASE2)
- The Back Pain Consortium Research Program Study (PHASE4)
- Duloxetine for LBP (PHASE4)
- Efficacy and Safety Study of Levomilnacipran Hydrochloride Extended-Release Capsules in Major Depressive Disorder (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Duloxetine 60mg CI brief — competitive landscape report
- Duloxetine 60mg updates RSS · CI watch RSS
- Ain Shams University portfolio CI